A Phase 3 interventional study of PJ009 and PJ009 Placebo in Short Bowel Syndrome, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Active, not recruiting at 8 sites in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Short Bowel Syndrome with a site in China — 4 open to participants now, 6 under way, 2 of them phase 3. Short Bowel Syndrome · China.
Among the 12 studies in Short Bowel Syndrome with a site in China, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 3, and was the 5th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →4 of the 12 studies in Short Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:
Chongqing Peg-Bio Biopharm Co., Ltd. · Sites in China
Ages 18+
Takeda · Sites in China
Ages 1–17
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shandong Qilu Stem Cells Engineering Co., Ltd. · Sites in China
Ages 1 days–28 days
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 27 across the 10 interventional studies, 23 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 12 have an industry lead sponsor. The 7 most frequent:
Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Chongqing Peg-Bio Biopharm Co., Ltd. has 3 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
| NCT07704047Chongqing Peg-Bio Biopharm Co., Ltd.A Clinical Study of FT1 in Patients With Short Bowel Syndrome | 2027-04-15 |
| NCT07691125Changchun GeneScience Pharmaceutical Co., Ltd.Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome | 2027-04-28 |
| NCT07319832TakedaA Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Short Bowel Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are:
Participants will
This is a multicenter, randomized, double-blind, placebo-controlled clinical study, aiming to evaluate the efficacy, safety, immunogenicity and pharmacokinetic of PJ009 in patients with short bowel syndrome requiring parenteral nutrition, using placebo as a control.
The trial is divided into 3 periods. Period 1 of this trial is the screening, optimization (if applicable, up to 8 weeks) and stabilization (4-8 weeks) period. At the end of the stabilization period, a baseline enrollment evaluation will be performed, and all eligible participants will enter the 24 weeks of double-blind treatment period (period 2). Period 3 is a 12-week open label extension to period 2. Safety follow-up assessments will be performed 4 weeks after the last dose in treatment period 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
With severe liver function impairment:
With renal function impairment:
Pancreatic abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous injections, 0.05 mg/kg once daily
Drug: PJ009
subcutaneous injections, once daily
Drug: PJ009 Placebo
subcutaneous injections, 0.05 mg/kg once daily
Also known as: Glucagon-Like Peptide 2 (GLP-2) analogue
subcutaneous injections, once daily
Also known as: GLP-2 analogue Placebo
Percentage of responders
A responder's PN/IV volume per week shows a reduction of at least 20% from baseline from week 20 to 24 in treatment period.
Time frame: Week 20 to 24 of treatment period
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Sep 2026, 24 months.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 24 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2026 → Sep 2026 and completion Apr 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Peg-Bio Biopharm Co., Ltd. →